Table 3 Cell cycle distribution after 24 h gemcitabine or dFdU under normoxia or hypoxia

MDA-MB-231 wt

0 nM dFdC/dFdU (N)

51.36

7.38

24.85

3.39

18.79

4.90

8 nM dFdC (N)

25.76

8.82

*

67.73

6.35

*

9.65

1.66

*

2 μM dFdU (N)

37.25

8.74

*

44.28

18.19

*

13.07

8.33

0 nM dFdC/dFdU (H)

48.61

6.04

29.69

7.94

18.41

8.85

8 nM dFdC (H)

41.95

17.94

53.28

17.17

*

8.81

1.43

*

2 μM dFdU (H)

49.31

11.21

37.79

12.98

5.46

0.22

MDA-MB-231 EV

0 nM dFdC/dFdU (N)

44.02

9.86

25.31

5.77

16.31

2.50

8 nM dFdC (N)

43.97

6.20

29.82

7.59

13.53

4.80

2 μM dFdU (N)

39.05

15.49

*

42.19

19.60

*

8.72

2.45

0 nM dFdC/dFdU (H)

51.31

11.10

27.28

9.94

10.17

4.03

¶

8 nM dFdC (H)

52.53

13.96

28.11

13.79

8.57

2.37

¶

2 μM dFdU (H)

50.51

14.73

33.15

19.84

6.56

2.31

MDA-MB-231 dnHIF

0 nM dFdC/dFdU (N)

49.22

8.46

23.60

4.67

16.97

2.19

8 nM dFdC (N)

41.89

18.19

31.65

15.59

13.38

7.75

2 μM dFdU (N)

41.77

18.66

*

44.09

14.32

*

7.94

1.98

0 nM dFdC/dFdU (H)

47.65

8.00

28.50

5.61

¶

13.03

3.99

¶

8 nM dFdC (H)

40.86

13.01

34.76

14.29

12.90

8.00

2 μM dFdU (H)

51.22

12.61

34.17

8.23

7.18

1.81